Expression Profiles of Five Common Cancer Membrane Protein Antigens Collected for the Development of Cocktail CAR-T Cell Therapies Applicable to Most Solid Cancer Patients
Preprint
- 29 January 2025
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Although CD19 CAR-T has been highly effective against B-cell blood cancers, there are few reports of successful treatments for solid cancers, probably because there are few protein antigens specifically expressed on the surface of the cancer cell membrane. The key to developing a groundbreaking CAR-T cell therapy effective against solid cancers is to "overcome the heterogeneity of cancer antigens." For this purpose, it is necessary to target multiple cancer antigens simultaneously. In this study, we performed immunohistochemical analysis of various solid cancer specimens using antibodies against ROBO1, EphB4, CLDN1, and LAT1 in addition to GPC3, which we have previously studied. These antigens were frequently expressed in various solid cancers but shown to be rarely expressed, with some exceptions, in non-cancerous normal organs adjacent to the cancer. In addition, it was revealed that the cell membrane antigens EphB4, CLDN1, and LAT1 are frequently expressed in various solid cancers. CAR-T cell therapy targeting these antigens may be a savior for many solid cancer patients. We will develop cancer immunotherapies that target these multiple common cancer membrane protein antigens.Keywords
All Related Versions
This publication has 29 references indexed in Scilit:
- Progress and challenges in glypican-3 targeting for hepatocellular carcinoma therapyExpert Opinion on Therapeutic Targets, 2024
- Amino acid transporter LAT1 (SLC7A5) as a molecular target for cancer diagnosis and therapeuticsPharmacology & Therapeutics, 2022
- First-in-human assessment of the novel LAT1 targeting PET probe 18F-FIMPBiochemical and Biophysical Research Communications, 2022
- Development of non-viral, ligand-dependent, EPHB4-specific chimeric antigen receptor T cells for treatment of rhabdomyosarcomaMolecular Therapy-Oncolytics, 2021
- Phase I study of glypican-3-derived peptide vaccine therapy for patients with refractory pediatric solid tumorsOncoImmunology, 2017
- Immunological efficacy of glypican-3 peptide vaccine in patients with advanced hepatocellular carcinomaOncoImmunology, 2017
- Efficacy of glypican-3-derived peptide vaccine therapy on the survival of patients with refractory ovarian clear cell carcinomaOncoImmunology, 2016
- Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patientsOncoImmunology, 2016
- Intratumoral peptide injection enhances tumor cell antigenicity recognized by cytotoxic T lymphocytes: a potential option for improvement in antigen-specific cancer immunotherapyCancer Immunology, Immunotherapy, 2012
- EphB4 provides survival advantage to squamous cell carcinoma of the head and neckInternational Journal of Cancer, 2006